Invasive meningococcal disease over five decades in the Faroe Islands: high incidence, low mortality, and implications for vaccination policy Authors: Gunnhild Helmsdal, Shahin Gaini Published: 2026 ABSTRACT Highlights•Invasive meningococcal disease is a severe but preventable infection. While incidence has declined in many countries, less is known about long-term patterns in small, isolated populations. We examined 45 years of data from the Faroe Islands, where incidence has been relatively high and vaccination is not part of the routine program, to better understand disease trends and inform prevention strategies.•We found that the Faroe Islands experienced a delayed and prolonged epidemic of invasive meningococcal disease with higher incidence than in neighboring countries, but consistently low mortality. Early recognition and prompt antibiotic treatment likely contributed to favorable outcomes.•Our findings highlight that small, isolated populations may experience different disease patterns and should not rely solely on trends from larger countries. The historically high incidence suggests that meningococcal vaccination strategies should be carefully evaluated. Local data are essential to guide prevention policies and optimize protection of the population. Introduction Invasive infection with the bacterium Neisseria meningitidis (commonly known as meningococci) is a rare but dangerous condition that can present as meningitis—affecting the membrane lining of the central nervous system—or as septicemia [[1], [2], [3], [4], [5], [6], [7], [8], [9]]. Mortality rates have been very high, up to 30%, but have improved significantly in recent years and are now 3-10% [1]. Meningococci are commonly found in the nasopharynx (10-30% of the population) but are rarely invasive [10,11]. However, the bacteria can be transmitted between individuals, causing disease [12]. Genetic polymorphisms related to the immune system, especially the innate immune system, have been associated with an increased risk of invasive meningococcal disease (IMD) [[13], [14], [15], [16]]. Twelve serogroups of meningococci are known to exist, with A, B, C, Y, and W-135 causing most disease. Globally, IMD is relatively rare, with reported annual incidence generally below 2 cases per 100,000 population, although incidence varies considerably by geographical region, age, serogroup, and occurrence of outbreaks [17]. Despite medical treatment, the disease can be fatal, especially with septicemia, or patients may be left with serious sequelae—physical, neurological, or psychological [[1], [2], [3], [4], [5], [6], [7], [8], [9]]. Treatment of the disease involves antibiotics, glucocorticoids, and intensive care treatment. Prophylactic antibiotic treatment is usually offered to the next of kin of infected people to eliminate meningococcal carriage, typically one oral dose of ciprofloxacin. Vaccines are available against serogroups A, B, C, W, X, and Y. Quadrivalent (ACWY) vaccines have been successfully introduced in Europe [18,19], and several countries have also implemented the vaccine against serogroup B meningococci in their national immunization programs (e.g. the United Kingdom, Ireland, Italy, and Portugal), with observed reductions in cases of IMD, especially in the United Kingdom [20]. During the 1970s, three meningococcal epidemics were seen in the Nordic region. In Finland, serogroup A was dominant, with a peak incidence of 14.6 per 100,000 population in 1974; in northern Norway, serogroup B was dominant, with a peak incidence of 23.9 per 100,000 population in 1975; and in Iceland in 1976, also mostly serogroup B, with a peak of 37.7 per 100,000 population [21], but with a shift to serogroup C from 1977 onward [22]. In the Faroe Islands, a small community of islands in the North Atlantic with a population of approximately 50,000, a very high number of cases of IMD have been observed. During the period 1978-1985, IMD incidence was extremely high in the Faroe Islands [23]. No apparent cause was found to explain the high incidence in the Faroe Islands. There were indices of high familial occurrence that could indicate genetic disposition, but only a few patients had minor aberrations in complement proteins [24]. However, the case numbers started to decrease after 1981, when the chemoprophylaxis for close contacts and family members changed from sulfamethizol or penicillin to rifampicin. Ciprofloxacin is currently being used in the Faroe Islands. The children's vaccination program in the Faroe Islands follows the Danish children’s vaccination program. It includes a 13-valent pneumococcal vaccine and a Haemophilus influenzae vaccine, but no meningococcal vaccine. Given the severity of the disease and the epidemic incidence observed 45 years ago, we conducted an epidemiological, population-based study of IMD in the Faroes from 1980 to 2025. The period up to the end of 1985 has been partly described in another study [23], when incidence was still very high, but no further evaluation has been conducted since. Methods IMD is a notifiable disease in the Faroe Islands that must be reported to the Chief Medical Officer. Cases of IMD have therefore been identified through the records of the Chief Medical Officer, the clinical microbiology laboratory at the National Hospital, and by extracting diagnosis codes for invasive meningococcal disease (International Classification of Diseases revision 8 and 10, 36.0-36.9 and A39.0-39.9, respectively) in patients admitted to the three hospitals of the Faroe Islands in the period 1980-2025. The epidemic is believed to have started around 1977, but microbiological facilities were not established before the end of the 1970s, so the case numbers are not fully accurate at the beginning of the period. The hospital journals were reviewed manually for the required information regarding the diagnosis. Inclusion criteria were a diagnosis of meningitis, septicemia, or both, with meningococcal etiology considered likely based on microbiological or clinical criteria as described by Weihe et al. in the study of IMD in the Faroe Islands in 1978-1980 [23]:a)Bacteriologically verified cases, comprising patients with positive cultures or polymerase chain reaction of meningococci from the cerebrospinal fluid (CSF) and/or blood, positive culture or polymerase chain reaction from a normally sterile site, or with positive microscopy of Gram-stained CSF and/or petechiae with the finding of Gram-negative diplococci.b)Non-verified but clinically definite cases comprising patients with petechiae or ecchymoses, combined with one or more of the following symptoms or findings: stiffness of the neck, headache, nausea, vomiting, stupor, laboratory findings in the CSF compatible with purulent meningitis, biochemical signs of disseminated intravascular coagulation, increased meningococcal antibody titer.c)Non-verified, not clinically definite cases with increased meningococcal antibody titer, comprising patients with a pattern of disease resulting in treatment of presumed meningococcal meningitis and/or septicemia, and who, after treatment, had a positive meningococcal antibody titer. a)Bacteriologically verified cases, comprising patients with positive cultures or polymerase chain reaction of meningococci from the cerebrospinal fluid (CSF) and/or blood, positive culture or polymerase chain reaction from a normally sterile site, or with positive microscopy of Gram-stained CSF and/or petechiae with the finding of Gram-negative diplococci. Bacteriologically verified cases, comprising patients with positive cultures or polymerase chain reaction of meningococci from the cerebrospinal fluid (CSF) and/or blood, positive culture or polymerase chain reaction from a normally sterile site, or with positive microscopy of Gram-stained CSF and/or petechiae with the finding of Gram-negative diplococci. b)Non-verified but clinically definite cases comprising patients with petechiae or ecchymoses, combined with one or more of the following symptoms or findings: stiffness of the neck, headache, nausea, vomiting, stupor, laboratory findings in the CSF compatible with purulent meningitis, biochemical signs of disseminated intravascular coagulation, increased meningococcal antibody titer. Non-verified but clinically definite cases comprising patients with petechiae or ecchymoses, combined with one or more of the following symptoms or findings: stiffness of the neck, headache, nausea, vomiting, stupor, laboratory findings in the CSF compatible with purulent meningitis, biochemical signs of disseminated intravascular coagulation, increased meningococcal antibody titer. c)Non-verified, not clinically definite cases with increased meningococcal antibody titer, comprising patients with a pattern of disease resulting in treatment of presumed meningococcal meningitis and/or septicemia, and who, after treatment, had a positive meningococcal antibody titer. Non-verified, not clinically definite cases with increased meningococcal antibody titer, comprising patients with a pattern of disease resulting in treatment of presumed meningococcal meningitis and/or septicemia, and who, after treatment, had a positive meningococcal antibody titer. Patients were excluded if they did not meet the above-mentioned criteria. Results A total of 234 cases of IMD were found through the records. Table 1 shows data about the IMD cases in the Faroe Islands in 1980-2025 presented in 5-year intervals. Of these, 155 cases were bacteriologically or microscopically verified (66%), 72 cases were clinically definite (31%), and seven (3%) were not clinically definite but had a subsequent positive meningococcal antibody titer.Table 1Characteristics of invasive meningococcal disease cases in the Faroe Islands by time period, 1980-2025.Table 1 dummy alt textPeriodCasesDemographic characteristicsCase verificationClinical presentationSerogroupMedian age,years (range)Male sex,n (%)Fatalities,nCulture or microscopy, nClinical,nIncreasedtiter, nMeningitis,nSepsis,nMeningitis andsepsis, nOther,nB,nC,nOther,nNon-groupable,nUnknown,n1980-19841504 (0-72)82 (54.7)7105423545640072800701985-1989514 (0-44)27 (52.9)33118232163022201261990-1994124 (0-39)7 (58.3)021006500400081995-199968.5 (1-73)4 (66.7)04114010210032000-20044NAaNAa03102100310002005-200961 (0-19)4 (66.7)06003110130022010-20142NAaNAa01011100100012015-20192NAaNAa02000101001012020-20251NAaNAa0100010000100Abbreviation: NA: not applicable.aAge and sex data are not presented because of the risk of case identification. Table 1Characteristics of invasive meningococcal disease cases in the Faroe Islands by time period, 1980-2025.Table 1 dummy alt textPeriodCasesDemographic characteristicsCase verificationClinical presentationSerogroupMedian age,years (range)Male sex,n (%)Fatalities,nCulture or microscopy, nClinical,nIncreasedtiter, nMeningitis,nSepsis,nMeningitis andsepsis, nOther,nB,nC,nOther,nNon-groupable,nUnknown,n1980-19841504 (0-72)82 (54.7)7105423545640072800701985-1989514 (0-44)27 (52.9)33118232163022201261990-1994124 (0-39)7 (58.3)021006500400081995-199968.5 (1-73)4 (66.7)04114010210032000-20044NAaNAa03102100310002005-200961 (0-19)4 (66.7)06003110130022010-20142NAaNAa01011100100012015-20192NAaNAa02000101001012020-20251NAaNAa0100010000100Abbreviation: NA: not applicable.aAge and sex data are not presented because of the risk of case identification. Characteristics of invasive meningococcal disease cases in the Faroe Islands by time period, 1980-2025. Abbreviation: NA: not applicable. Age and sex data are not presented because of the risk of case identification. Most patients were young; 91% were under 20 years of age, and 53% were 4 years old or younger. The sex distribution was somewhat equal, with slightly more males than females observed (54% vs 46%, respectively). Some seasonal variation was observed, with most cases in January (14%) and overall slightly higher case numbers in the winter season (November to January), accounting for a total of 30% of the cases. Peak incidence of IMD was seen in 1981, at 100 per 100,000 population, followed by a gradual but prolonged decrease until 1990, when incidence was 13 per 100,000 population. Since then, incidence has been stable around 0-7 per 100,000 population, with a mean of 1.6 per 100,000 population. Figure 1 shows the incidence of IMD during the period.Figure 1Incidence of invasive meningococcal disease in the Faroe Islands 1980-2025 (cases per 100,000 population).Figure 1 dummy alt text Incidence of invasive meningococcal disease in the Faroe Islands 1980-2025 (cases per 100,000 population). In 47% of the cases, no growth was observed in cultures of biological material or cultures were not performed. However, in some of these cases, Gram-negative diplococci were observed on direct microscopy of blood, spinal fluid, or petechiae, and in some cases, antibody tests were later positive. Most of these patients had received antibiotics prior to admission. Therefore, serogrouping was not possible in these cases. The predominant serogroup was N. meningitidis serogroup B. During 1980-1984, serogroup B accounted for 89% of IMD [25]. From 1985 to 2025, the distribution of serogroups shifted to 77% serogroup B, 16% serogroup C, and 7% other or non-groupable strains. The mortality rate in the period 1978-1985 was 5.4% and was presented in another study [23]. In 1986, two children died, and since then, no deaths have been registered. Other bacterial etiologies of meningitis identified during the period were Haemophilus influenzae, Escherichia coli, Streptococcus pneumoniae, Staphylococcus aureus, and Listeria monocytogenes. The incidence of invasive disease caused by these bacterial types was 0-4/100,000 and remained unchanged during the period (results not shown). Discussion This study provides a long-term, population-based overview of IMD in the Faroe Islands. Incidence was already high in 1980, the first year described in the present study. The incidence of IMD had increased in the second half of the 1970s, so it is believed that the epidemic started around 1977, as the incidence in 1978 was 26 per 100,000 population and was 56 per 100,000 population in 1979 (non-verified IMD cases due to inadequate diagnostic facilities). The epidemic, therefore, peaked somewhat later than in other countries in the region that also experienced increased IMD numbers. The reasons for this are not fully understood but may reflect transmission dynamics in a small, relatively isolated population. The remoteness of the Faroe Islands could explain the later occurrence of the epidemic, but the prolonged period compared with that in other countries is somewhat more puzzling. Nevertheless, the decline in incidence coincided with changes in prophylactic antibiotic treatment, which may have contributed to reduced transmission. Together, these findings suggest distinct epidemic dynamics compared with those in other Nordic countries. As mentioned, in almost half of the cases, the serogroup was not identified. Some of these were defined as having IMD by microscopy of Gram-negative diplococci in spinal fluid, blood, or petechiae, or by a subsequent positive antibody test; others were diagnosed only on clinical presentation. This introduces limitations in our data and may lead to an overestimation of incidence, particularly in the early years. On the other hand, these patients showed signs of septicemia and meningeal irritation as well as petechiae, indicating a high probability of IMD. As mentioned, microbial cultures were, unfortunately, often not performed. This may have been due to the long distance to the reference laboratory in Denmark and the expectation that the result would not change antibiotic treatment. In many cases, the patient would have finished treatment and been discharged by the time the result arrived. Additionally, patients without microbiological growth had received antibiotics prior to admission, so bacterial growth likely decreased in culture. This was recommended practice for a doctor in the primary sector diagnosing a possible case of meningococcal meningitis, typically during a house call or at a local practice. This was particularly important when patients required transport over long distances to hospital care. The low mortality rate in the Faroe Islands could be due to several factors: first, the virulence of the strain in the Faroe Islands could be lower than that of strains detected in other countries; second, increased awareness of IMD symptoms following the high number of cases in this small society; and finally, the rapid recognition and early treatment initiated by general practitioners likely contributed to improved outcomes. The absence of deaths after 1986 is also notable and contrasts with reported case fatality rates of 3-10% in other settings. Our report shows that IMD remains present in the Faroe Islands to date. Although an effective vaccine against serogroup B meningococci has been on the market for the past 10 years and has been added to several national children’s vaccination programs in Europe, it has not been added to the children's vaccination program in the Faroe Islands. Reports from the Faroese National Pharmacy also indicate that very few vaccines against serogroup B IMD have been sold in the Faroe Islands (personal communication with the National Pharmacy). In the neighboring country of Iceland, a comparable setting to the Faroe Islands, vaccination against serogroup C IMD is part of the vaccination program. However, based on low incidence of IMD and low carriage of serogroup B meningococci, it has been estimated that introducing a serogroup B vaccine in Iceland is not currently warranted in the national immunization program [26]. Fortunately, the incidence of IMD in the Faroe Islands has been low for 35 years. Nevertheless, carriage studies are needed to inform vaccination policy in the Faroe Islands. Conclusions The incidence of IMD, predominantly serogroup B disease, was historically very high in the Faroes. The number of cases has since decreased substantially and is similar to that in countries in the region. The potential role of childhood meningococcal vaccination should be further evaluated. Funding Sjúkrakassagrunnurin (The Faroese health security fund). Ethical approval According to the Faroese law on scientific ethics, the study did not require ethical approval. CRediT authorship contribution statement Gunnhild Helmsdal: Writing – review & editing, Writing – original draft, Funding acquisition, Formal analysis, Data curation, Conceptualization. Shahin Gaini: Writing – review & editing, Funding acquisition, Conceptualization. Declaration of competing interest The authors have no competing interests to declare.